Chronic Cough - Pipeline Review, H1 2016

  • ID: 3714973
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ario Pharma Ltd
  • AstraZeneca Plc
  • Conrig Pharma ApS
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • NeRRe Therapeutics Ltd
  • MORE
Chronic Cough - Pipeline Review, H1 2016

Summary

‘Chronic Cough - Pipeline Review, H1 2016’, provides an overview of the Chronic Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Cough
- The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects
- The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Cough

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ario Pharma Ltd
  • AstraZeneca Plc
  • Conrig Pharma ApS
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • NeRRe Therapeutics Ltd
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Chronic Cough Overview

Therapeutics Development

Pipeline Products for Chronic Cough - Overview

Pipeline Products for Chronic Cough - Comparative Analysis

Chronic Cough - Therapeutics under Development by Companies

Chronic Cough - Therapeutics under Investigation by Universities/Institutes

Chronic Cough - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Chronic Cough - Products under Development by Companies

Chronic Cough - Products under Investigation by Universities/Institutes

Chronic Cough - Companies Involved in Therapeutics Development

Afferent Pharmaceuticals, Inc.

Ario Pharma Ltd

AstraZeneca Plc

Conrig Pharma ApS

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

GW Pharmaceuticals Plc

NeRRe Therapeutics Ltd

Patara Pharma, Inc.

Chronic Cough - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AF-219 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GRC-17536 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GSK-2339345 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lesogaberan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

orvepitant maleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-1226 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ST-015 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

XEND-0501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chronic Cough - Recent Pipeline Updates

Chronic Cough - Dormant Projects

Chronic Cough - Discontinued Products

Chronic Cough - Product Development Milestones

Featured News & Press Releases

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chronic Cough, H1 2016

Number of Products under Development for Chronic Cough - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016

Chronic Cough - Pipeline by Ario Pharma Ltd, H1 2016

Chronic Cough - Pipeline by AstraZeneca Plc, H1 2016

Chronic Cough - Pipeline by Conrig Pharma ApS, H1 2016

Chronic Cough - Pipeline by GlaxoSmithKline Plc, H1 2016

Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016

Chronic Cough - Pipeline by GW Pharmaceuticals Plc, H1 2016

Chronic Cough - Pipeline by NeRRe Therapeutics Ltd, H1 2016

Chronic Cough - Pipeline by Patara Pharma, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Chronic Cough Therapeutics - Recent Pipeline Updates, H1 2016

Chronic Cough - Dormant Projects, H1 2016

Chronic Cough - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Chronic Cough, H1 2016

Number of Products under Development for Chronic Cough - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Afferent Pharmaceuticals, Inc.
Ario Pharma Ltd
AstraZeneca Plc
Conrig Pharma ApS
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GW Pharmaceuticals Plc
NeRRe Therapeutics Ltd
Patara Pharma, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll